Compare Citius Pharmaceuticals Inc (CTXR) vs Kinder Morgan Inc (KMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Kinder Morgan Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Kinder Morgan Inc trades at $32.5 (market cap $72.40B). The key difference: Kinder Morgan Inc is far larger — about 4945.4× Citius Pharmaceuticals Inc's market cap, and Kinder Morgan Inc pays a 3.61% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | KMI | |
|---|---|---|
Market Cap | $14.64M | $72.40B |
Sector | Health | Energy |
52-Week High | $1.82 | $34.31 |
52-Week Low | $0.53 | $25.84 |
Enterprise Value | $10.86M | $104.27B |
Dividend Yield | — | 3.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
KMI trades at $32.24, up 0.37% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $0.48, and revenue growth is projected to reach $17.5B in 2026. Analyst sentiment is mixed but leans positive, with 47% recommending a buy, supported by a stable dividend and a $10.1B project backlog focused on natural gas infrastructure.
The outlook for KMI is favorable, driven by rising LNG demand and contracted cash flows, though risks include commodity price volatility and high debt levels. The stock offers a solid dividend yield and growth potential from infrastructure investments, making it attractive for income and growth investors despite macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Kinder Morgan Inc
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →
